This presentation provides an overview on the epidemiology of MG. Though MG is a rare disease, the number of patients afflicted with this disease is growing globally.
This presentation introduces muscle-specific kinase (MuSK) MG. MuSK is an integral postsynaptic protein that is critical for neuromuscular junction development and maintenance.
he objective of this study was to compare trends in functional status, MG exacerbations, and health care resource utilization (HRU) outcomes in patients with refractory and nonrefractory gMG utilizing the Myasthenia Gravis Foundation of America (MGFA) patient registry.
his presentation provides an overview of a select number of clinical outcome measures that can be utilized when evaluating patients diagnosed with MG, including the QMG, the MG-ADL, and the MGC, among others.
This presentation provides an overview of the international treatment guidelines for the management of MG, which were established by a Task Force appointed by the Myasthenia Gravis
Treatment Guidelines
For US Healthcare Professionals Only
The contents of this website are intended for US healthcare professionals only.
By clicking “Continue,” you are confirming that you are a US healthcare professional.
Important note:
This contact form is not intended to be used to order prescribed medications, nor should it be used to report personal health concerns or adverse events, in case of such events:
for patients: if you wish to report an adverse event related to one of our products, please contact your healthcare provider. In addition you can contact us using the webform available here
for healthcare professionals: if you wish to report an adverse event related to one of our products , please follow the current regulatory procedure in force in your country or contact us using the webform available here.
